



JAN - 7 2003

Food and Drug Administration
Rockville MD 20857

NADA 093-107

M. Elizabeth McKenzie
Associate Director, U.S. Regulatory Affairs
Pfizer Inc., Animal Health Group
150 East 42nd Street
New York, New York 10017

Dear Ms. McKenzie,

This is in reference to your drug experience report dated July 11, 2002, concerning the prescription drug Albon®, sulfadimethoxine, NADA 093-107. One panel of brochure # LAT02013 includes promotional material for Albon® sustained -release boluses.

This promotional material for Albon® lists indications for use, dosage forms, and duration of treatment. However, this material is not fairly balanced with the warnings, cautions, and slaughter withdrawal information approved for Albon®.

At this time we request that this and similar promotional materials be stopped.

Please inform us of your intentions as soon as possible or within 30 days of the receipt date of this letter. If you have any questions, you may contact us at (301) 827-6642.6642.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Lynn O. Post", written over a horizontal line.

Lynn O. Post, D.V.M., Ph.D.
Acting Division Director
Division of Surveillance, HFV-210
Center for Veterinary Medicine